Neuropeptide Y receptors as therapeutic targets in anxiety and depression

Drug Development Research

Volumn 65, Issue 4, 2005, Pages 301-308

  Sajdyk, Tammy J ^a,b  

^a INDIANA UNIVERSITY MEDICAL CENTER   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anxiety; Homeostasis; Peptides; Stress

Indexed keywords

ANTICONVULSIVE AGENT; DIAZEPAM; ETIRACETAM; N METHYL BETA CARBOLINE 3 CARBOXAMIDE; N2 DIPHENYLACETYL N (4 UREIDOMETHYLBENZYL)ARGININAMIDE; NALPHA (DIPHENYLACETYL) N (4 HYDROXYBENZYL) DEXTRO ARGININAMIDE; NEUROPEPTIDE Y [2-36]; NEUROPEPTIDE Y RECEPTOR; NEUROPEPTIDE Y RECEPTOR AGONIST; NEUROPEPTIDE Y RECEPTOR ANTAGONIST; NEUROPEPTIDE Y1 RECEPTOR; NEUROPEPTIDE Y1 RECEPTOR ANTAGONIST; NEUROPEPTIDE Y2 RECEPTOR; NEUROPEPTIDE Y4 RECEPTOR; NEUROPEPTIDE Y5 RECEPTOR; NEUROPEPTIDE Y5 RECEPTOR ANTAGONIST; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG;

ANXIETY; BEHAVIOR; CEREBROSPINAL FLUID; DEPRESSION; DRUG TARGETING; ENDOCRINE FUNCTION; FEEDING; MENTAL DISEASE; MOOD DISORDER; NONHUMAN; REVIEW; STRESS;

EID: 29544447525     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/ddr.20031     Document Type: Review

References (98)

1. Aston-Jones G, Rajkowski J, Kubiak P, Valentino RJ, Shipley MT. 1996. Role of the locus coeruleus in emotional activation. Prog Brain Res 107:379-402.
2. Bailer UF, Kaye WH. 2003. A review of neuropeptide and neuroendocrine dysregulation in anorexia and bulimia nervosa. Curr Drug Targets CNS Neurol Disord 2:53-59.
3. Berglund MM, Hipskind PA, Gehlert DR. 2003. Recent developments in our understanding of the physiological role of PP-fold peptide receptor subtypes. Exp Biol Med (Maywood) 228:217-244.
4. Broqua P, Wettstein JG, Rocher MN, Gauthier-Martin B, Junien JL. 1995. Behavioral effects of neuropeptide Y receptor agonists in the elevated plus-maze and fear-potentiated startle procedures. Behav Pharmacol 6:215-222.
5. Caberlotto L, Hurd YL. 1999. Reduced neuropeptide Y mRNA expression in the prefrontal cortex of subjects with bipolar disorder. Neuroreport 10:1747-1750.
6. Caberlotto L, Hurd YL. 2001. Neuropeptide Y Y(1) and Y(2) receptor mRNA expression in the prefrontal cortex of psychiatric subjects. Relationship of Y(2) subtype to suicidal behavior. Neuropsychopharmacology 25:91-97.
7. Caberlotto L, Jimenez P, Overstreet DH, Hurd YL, Mathe AA, Fuxe K. 1999. Alterations in neuropeptide Y levels and Y1 binding sites in the Flinders Sensitive Line rats, a genetic animal model of depression. Neurosci Lett 265:191-194.
8. Colmers WF, Bleakman D. 1994. Effects of neuropeptide Y on the electrical properties of neurons. Trends Neurosci 17:373-379.
9. De Kloet E, Vreugdenhil E, Oitzl M, Joels M. 1998. Brain corticosteroid receptor balance in health and disease. Endocrine Rev 19:269-301.
10. Dumont Y, Jacques D, Bouchard P, Quirion R. 1998. Species differences in the expression and distribution of the neuropeptide Y Y1, Y2, Y4, and Y5 receptors in rodents, guinea pig, and primates brains. J Comp Neurol 402:372-384.
11. Dumont Y, Moyse E, Fournier A, Quirion R. 2005. Evidence for the existence of an additional class of neuropeptide Y receptor sites in the rat brain. J Pharmacol Exp Ther 315:99-108.
12. Fuxe K, Agnati LF, Harfstrand A, Zini I, Tatemoto K, Pich EM, Hokfelt T, Mutt V, Terenius L. 1983. Central administration of neuropeptide Y induces hypotension bradypnea and EEG synchronization in the rat. Acta Physiol Scand 118:189-192.
13. Gehlert DR, Yang P, George C, Wang Y, Schober D, Gackenheimer S, Johnson D, Beavers LS, Gadski RA, Baez M. 2001. Cloning and characterization of rhesus monkey neuropeptide Y receptor subtypes. Peptides 22:343-350.
14. Gower AJ, Falter U, Lamberty Y. 2003. Anxiolytic effects of the novel anti-epileptic drug levetiracetam in the elevated plus-maze test in the rat. Eur J Pharmacol 481:67-74.
15. Greenberg PE, Sisitsky T, Kessler RC, Finkelstein SN, Berndt ER, Davidson JR, Ballenger JC, Fyer AJ. 1999. The economic burden of anxiety disorders in the 1990s. J Clin Psychiatry 60:427-435.
16. Gribkoff VK, Pieschl RL, Wisialowski TA, van den Pol AN, Yocca FD. 1998. Phase shifting of circadian rhythms and depression of neuronal activity in the rat suprachiasmatic nucleus by neuropeptide Y: mediation by different receptor subtypes. J Neurosci 18:3014-3022.
17. Groneberg DA, Folkerts G, Peiser C, Chung KF, Fischer A. 2004. Neuropeptide Y (NPY). Pulm Pharmacol Ther 17:173-180.
18. Heilig M. 1995. Antisense inhibition of neuropeptide Y (NPY)-Y1 receptor expression blocks the anxiolytic-like action of NPY in amygdala and paradoxically increases feeding. Regul Pept 59:201-205.
19. Heilig M. 2004. The NPY system in stress, anxiety and depression. Neuropeptides 38:213-224.
20. Heilig M, Murison R. 1987a. Intracerebroventricular neuropeptide Y protects against stress-induced gastric erosion in the rat. Eur J Pharmacol 137:127-129.
21. Heilig M, Murison R. 1987b. Intracerebroventricular neuropeptide Y suppresses open field and home cage activity in the rat. Regul Pept 19:221-231.
22. Heilig M, Thorsell A. 2002. Brain neuropeptide Y (NPY) in stress and alcohol dependence. Rev Neurosci 13:85-94.
23. Heilig M, Widerlov E. 1990. Neuropeptide Y: an overview of central distribution, functional aspects, and possible involvement in neuropsychiatric illnesses. Acta Psychiatr Scand 82:95-114.
24. Heilig M, Wahlestedt C, Ekman R, Widerlov E. 1988. Antidepressant drugs increase the concentration of neuropeptide Y (NPY)-like immunoreactivity in the rat brain. Eur J Pharmacol 147:465-467.
25. Heilig M, Soderpalm B, Engel JA, Widerlov E. 1989. Centrally administered neuropeptide Y (NPY) produces anxiolytic-like effects in animal anxiety models. Psychopharmacologia 98:524-529.
26. Heilig M, McLeod S, Koob GK, Britton KT. 1992. Anxiolytic-like effect of neuropeptide Y (NPY), but not other peptides in an operant conflict test. Regul Pept 41:61-69.
27. Heilig M, McLeod S, Brot M, Heinrichs SC, Menzaghi F, Koob GF, Britton KT. 1993. Anxiolytic-like action of neuropeptide Y: mediation by Y1 receptors in amygdala, and dissociation from food intake effects. Neuropsychopharmacology 8:357-363.
28. Heilig M, Zachrisson O, Thorsell A, Ehnvall A, Mottagni-Tabar S, Sjogren M, Asberg M, Ekman R, Wahlestedt C, Agren H. 2004. Decreased cerebrospinal fluid neuropeptide Y (NPY) in patients with treatment refractory unipolar major depression: preliminary evidence for association with preproNPY gene polymorphism. J Psychiatr Res 38:113-121.
29. Husum H, Mathe AA. 2002. Early life stress changes concentrations of neuropeptide Y and corticotropin-releasing hormone in adult rat brain. Lithium treatment modifies these changes. Neuropsychopharmacology 27:756-764.
30. Husum H, Mikkelsen JD, Hogg S, Mathe AA, Mork A. 2000. Involvement of hippocampal neuropeptide Y in mediating the chronic actions of lithium, electroconvulsive stimulation and citalopram. Neuropharmacology 39:1463-1473.
31. Husum H, Vasquez PA, Mathe AA. 2001. Changed concentrations of tachykinins and neuropeptide Y in brain of a rat model of depression: lithium treatment normalizes tachykinins. Neuropsychopharmacology 24:183-191.
32. Husum H, Gruber SH, Bolwig TG, Mathe AA. 2002. Extracellular levels of NPY in the dorsal hippocampus of freely moving rats are markedly elevated following a single electroconvulsive stimulation, irrespective of anticonvulsive Y1 receptor blockade. Neuropeptides 36:363-369.
33. Husum H, Bolwig TG, Sanchez C, Mathe AA, Hausen SL. 2004. Levetiracetam prevents changes in levels of brain-derived neurotrophic factor and neuropeptide Y mRNA and of Y1- and Y5-like receptors in the hippocampus of rats undergoing amygdala kindling: implications for antiepileptogenic and mood-stabilizing properties. Epilepsy Behav 5:204-215.
34. Illes P, Finta EP, Nieber K. 1993. Neuropeptide Y potentiates via Y2-receptors the inhibitory effect of noradrenaline in rat locus coeruleus neurones. Naunyn Schmiedebergs Arch Pharmacol 348:546-548.
35. Ishida H, Shirayama Y, Iwata M, Kawahara R. 2005. Subchronic treatment with imipramine ameliorates the decreased number in neuropeptide Y-positive cells in the hippocampus of learned helplessness rats. Brain Res 1046:239-243.
36. Jimenez-Vasquez PA, Overstreet DH, Mathe AA. 2000a. Neuropeptide Y in male and female brains of Flinders Sensitive Line, a rat model of depression. Effects of electroconvulsive stimuli. J Psychiatr Res 34:405-412.
37. Jimenez Vasquez PA, Salmi P, Ahlenius S, Mathe AA. 2000b. Neuropeptide Y in brains of the Flinders Sensitive Line rat, a model of depression. Effects of electroconvulsive stimuli and d-amphetamine on peptide concentrations and locomotion. Behav Brain Res 111:115-123.
38. Kask A, Rago L, Harro J. 1998a. Anxiogenic-like effect of the NPY Y1 receptor antagonist BIBP3226 administered into the dorsal periaqueductal gray matter in rats. Regul Pept 75-76:255-262.
39. Kask A, Rago L, Harro J. 1998b. Anxiolytic-like effect of neuropeptide Y (NPY) and NPY13-36 microinjected into vicinity of locus coeruleus in rats. Brain Res 788:345-348.
40. Kask A, Rago L, Harro J. 1998c. NPY Y1 receptors in the dorsal periaqueductal gray matter regulate anxiety in the social interaction test. NeuroReport 9:2713-2716.
41. Kask A, Eller M, Oreland L, Harro J. 2000. Neuropeptide Y attenuates the effect of locus coeruleus denervation by DSP-4 treatment on social behaviour in the rat. Neuropeptides 34:58-61.
42. Kask A, Nguyen HP, Pabst R, Von Horsten S. 2001. Neuropeptide Y Y1 receptor-mediated anxiolysis in the dorsocaudal lateral septum: functional antagonism of corticotropin-releasing hormone-induced anxiety. Neuroscience 104:799-806.
43. Kask A, Harro J, von Horsten S, Redrobe JP, Dumont Y, Quirion R. 2002. The neurocircuitry and receptor subtypes mediating anxiolytic-like effects of neuropeptide Y. Neurosci Biobehav Rev 26:259-283.
44. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen HU, Kendler KS. 1994. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 51:8-19.
45. King PJ, Widdowson PS, Doods HN, Williams G. 1999. Regulation of neuropeptide Y release by neuropeptide Y receptor ligands and calcium channel antagonists in hypothalamic slices. J Neurochem 73:641-646.
46. King PJ, Williams G, Doods H, Widdowson PS. 2000. Effect of a selective neuropeptide Y Y(2) receptor antagonist, BIIE0246 on neuropeptide Y release. Eur J Pharmacol 396:R1-R3.
47. Krysiak R, Obuchowicz E, Herman ZS. 1999. Diazepam and buspirone alter neuropeptide Y-like immunoreactivity in rat brain. Neuropeptides 33:542-549.
48. Larsen PJ, Sheikh SP, Jakobsen CR, Schwartz TW, Mikkelsen JD. 1993. Regional distribution of putative NPY Y1 receptors and neurons expressing Y1 mRNA in forebrain areas of the rat central nervous system. Eur J Neurosci 5:1622-1637.
49. Madsen TM, Greisen MH, Nielsen SM, Bolwig TG, Mikkelsen JD. 2000. Electroconvulsive stimuli enhance both neuropeptide Y receptor Y1 and Y2 messenger RNA expression and levels of binding in the rat hippocampus. Neuroscience 98:33-39.
50. Magni P. 2003. Hormonal control of the neuropeptide Y system. Curr Protein Pept Sci 4:45-57.
51. Makino S, Baker RA, Smith MA, Gold PW. 2000. Differential regulation of neuropeptide Y mRNA expression in the arcuate nucleus and locus coeruleus by stress and antidepressants. J Neuroendocrinol 12:387-395.
52. Mathe AA. 1999. Neuropeptides and electroconvulsive treatment. J Ect 15:60-75.
53. Mathe AA, Jimenez PA, Theodorsson E, Stenfors C. 1998. Neuropeptide Y, neurokinin A and neurotensin in brain regions of Fawn Hooded "depressed", Wistar, and Sprague Dawley rats. Effects of electroconvulsive stimuli. Prog Neuropsychopharmacol Biol Psychiatry 22:529-546.
54. Mikkelsen JD, Woldbye D, Kragh J, Larsen PJ, Bolwig TG. 1994. Electroconvulsive shocks increase the expression of neuropeptide Y (NPY) mRNA in the piriform cortex and the dentate gyrus. Brain Res Mol Brain Res 23:317-322.
55. Morgan CA 3rd, Wang S, Southwick SM, Rasmusson A, Hazlett G, Hauger RL, Charney DS. 2000. Plasma neuropeptide-Y concentrations in humans exposed to military survival training. Biol Psychiatry 47:902-909.
56. Nakajima M, Inui A, Asakawa A, Momose K, Ueno N, Teranishi A, Baba S, Kasuga M. 1998. Neuropeptide Y produces anxiety via Y2-type receptors. Peptides 19:359-363.
57. Nurnberger JI Jr, Wiegand R, Bucholz K, O'Connor S, Meyer ET, Reich T, Rice J, Schuckit M, King L, Petti T, Bierut L, Hinrichs AL, Kuperman S, Hesselbrock V, Porjesz B. 2004. A family study of alcohol dependence: coaggregation of multiple disorders in relatives of alcohol-dependent probands. Arch Gen Psychiatry 61:1246-1256.
58. Oberto A, Panzica G, Altruda F, Eva C. 2000. Chronic modulation of the GABA(A) receptor complex regulates Y1 receptor gene expression in the medial amygdala of transgenic mice. Neuropharmacology 39:227-234.
59. Parker MS, Parker SL, Kane JK. 2004. Internalization of neuropeptide Y Y1 and Y5 and of pancreatic polypeptide Y4 receptors is inhibited by lithium in preference to sodium and potassium ions. Regul Pept 118:67-74.
60. Parker RM, Herzog H. 1999. Regional distribution of Y-receptor subtype mRNAs in rat brain. European J Neurosci 11:1431-1448.
61. Peters J, Van Kammen DP, Gelernter J, Yao J, Shaw D. 1990. Neuropeptide Y-like immunoreactivity in schizophrenia. Relationships with clinical measures. Schizophr Res 3:287-294.
62. Pich EM, Agnati LF, Zini I, Marrama P, Carani C. 1993. Neuropeptide Y produces anxiolytic effects in spontaneously hypertensive rats. Peptides 14:909-912.
63. Pons J, Lee EW, Li L, Kitlinska J. 2004. Neuropeptide Y: multiple receptors and multiple roles in cardiovascular diseases. Curr Opin Investig Drugs 5:957-962.
64. Rasmusson AM, Hauger RL, Morgan CA, Bremner JD, Charney DS, Southwick SM. 2000. Low baseline and yohimbine-stimulated plasma neuropeptide Y (NPY) levels in combat-related PTSD. Biol Psychiatry 47:526-539.
65. Redrobe JP, Dumont Y, Quirion R. 2002. Neuropeptide Y (NPY) and depression: from animal studies to the human condition. Life Sci 71:2921-2937.
66. Redrobe JP, Dumont Y, Herzog H, Quirion R. 2003. Neuropeptide Y (NPY) Y2 receptors mediate behaviour in two animal models of anxiety: evidence from Y2 receptor knockout mice. Behav Brain Res 141:251-255.
67. Rimondini R, Thorsell A, Heilig M. 2005. Suppression of ethanol self-administration by the neuropeptide Y (NPY) Y2 receptor antagonist BIIE0246: evidence for sensitization in rats with a history of dependence. Neurosci Lett 375:129-133.
68. Rush AJ, Zimmerman M, Wisniewski SR, Fava M, Hollon SD, Warden D, Biggs MM, Shores-Wilson K, Shelton RC, Luther JF, Thomas B, Trivedi MH. 2005. Comorbid psychiatric disorders in depressed outpatients: Demographic and clinical features. J Affect Disord 87:43-55.
69. Safadi G, Bradwejn J. 1995. Relationship of panic disorder to posttraumatic stress disorder. Arch Gen Psychiatry 52:76-78.
70. Sajdyk TJ, Fitz SD, Shekhar A. In press. Role of neuropeptide Y in stress response regulation. Stress.
71. Sajdyk TJ, Vandergriff MG, Gehlert DR. 1999a. Amygdalar neuropeptide Y Y1 receptors mediate the anxiolytic-like actions of neuropeptide Y in the social interaction test. Eur J Pharmacol 368:143-147.
72. Sajdyk TJ, Vandergriff MG, Gehlert DR. 1999b. Amygdalar neuropeptide Y Y1 receptors mediate the anxiolytic-like actions of neuropeptide Y in the social interaction test. Eur J Pharmacol 368:143-147.
73. Sajdyk TJ, Schober DA, Gehlert DR. 2002a. Neuropeptide Y receptor subtypes in the basolateral nucleus of the amygdala modulate anxiogenic responses in rats. Neuropharmacology 43:1165-1172.
74. Sajdyk TJ, Schober DA, Smiley DL, Gehlert DR. 2002b. Neuropeptide Y-Y2 receptors mediate anxiety in the amygdala. Pharmacol Biochem Behav 71:419-423.
75. Sajdyk TJ, Fitz SD, Shekhar A. 2004a. Neuropeptide Y (NPY) microinjections into the basolateral amygdala prevents the behavioral expression of long-term corticotropin-releasing factor (CRF)-mediated anxiety-like behaviour. San Diego, California.
76. Sajdyk TJ, Shekhar A, Gehlert DR. 2004b. Interactions between NPY and CRF in the amygdala regulate emotionality. Neuropeptides 38:225-234.
77. Simon NM, Worthington JJ, Doyle AC, Hoge EA, Kinrys G, Fischmann D, Link N, Pollack MH. 2004. An open-label study of levetiracetam for the treatment of social anxiety disorder. J Clin Psychiatry 65:1219-1222.
78. Sorensen G, Lindberg C, Wortwein G, Bolwig TG, Woldbye DP. 2004. Differential roles for neuropeptide Y Y1 and Y5 receptors in anxiety and sedation. J Neurosci Res 77:723-729.
79. Steiger A. 2003. Sleep and endocrine regulation. Front Biosci 8:s358-s376.
80. Sullivan GM, Coplan JD, Kent JM, Gorman JM. 1999. The noradrenergic system in pathological anxiety: a focus on panic with relevance to generalized anxiety and phobias. Biol Psychiatry 46:1205-1218.
81. Sweerts BW, Jarrott B, Lawrence AJ. 2000. Acute and chronic restraint stress: effects on [125I]-galanin binding in normotensive and hypertensive rat brain. Brain Res 873:318-329.
82. Tatemoto K. 2004. Neuropeptide Y: History and overview. Handbook of experimental pharmacology. Berlin: Springer-Verlag. p 1-21.
83. Thorsell A, Svensson P, Wiklund L, Sommer W, Ekman R, Heilig M. 1998. Suppressed neuropeptide Y (NPY) mRNA in rat amygdala following restraint stress. Regul Pept 75-76:247-254.
84. Thorsell A, Carlsson K, Ekman R, Heilig M. 1999. Behavioral and endocrine adaptation, and up-regulation of NPY expression in rat amygdala following repeated restraint stress. NeuroReport 10:3003-3007.
85. Thorsell A, Michalkiewicz M, Dumont Y, Quirion R, Caberlotto L, Rimondini R, Mathe AA, Heilig M. 2000. Behavioral insensitivity to restraint stress, absent fear suppression of behavior and impaired spatial learning in transgenic rats with hippocampal neuropeptide Y overexpression. Proc Natl Acad Sci USA 97:12852-12857.
86. Tovote P, Meyer M, Beck-Sickinger AG, von Horsten S, Ove Ogren S, Spiess J, Stiedl O. 2004. Central NPY receptor-mediated alteration of heart rate dynamics in mice during expression of fear conditioned to an auditory cue. Regul Pept 120:205-214.
87. Tschenett A, Singewald N, Carli M, Balducci C, Salchner P, Vezzani A, Herzog H, Sperk G. 2003. Reduced anxiety and improved stress coping ability in mice lacking NPY-Y2 receptors. Eur J Neurosci 18:143-148.
88. Wahlestedt C, Blendy JA, Kellar KJ, Heilig M, Widerlov E, Ekman R. 1990. Electroconvulsive shocks increase the concentration of neocortical and hippocampal neuropeptide Y (NPY)-like immunoreactivity in the rat. Brain Res 507:65-68.
89. Wahlestedt C, Pich EM, Koob GF, Yee F, Heilig M. 1993. Modulation of anxiety and neuropeptide Y-Y1 receptors by antisense oligodeoxynucleotides. Science 259:528-531.
90. Watkins KE, Hunter SB, Wenzel SL, Tu W, Paddock SM, Griffin A, Ebener P. 2004. Prevalence and characteristics of clients with co-occurring disorders in outpatient substance abuse treatment. Am J Drug Alcohol Abuse 30:749-764.
91. Westrin A, Engstom G, Ekman R, Traskman-Bendz L. 1998. Correlations between plasma-neuropeptides and temperament dimensions differ between suicidal patients and healthy controls. J Affect Disord 49:45-54.
92. Westrin A, Ekman R, Traskman-Bendz L. 1999. Alterations of corticotropin releasing hormone (CRH) and neuropeptide Y (NPY) plasma levels in mood disorder patients with a recent suicide attempt. Eur Neuropsychopharmacol 9:205-211.
93. Widdowson PS, Ordway GA, Halaris AE. 1992. Reduced neuropeptide Y concentrations in suicide brain. J Neurochem 59:73-80.
94. Widerlov E, Lindstrom LH, Wahlestedt C, Ekman R. 1988. Neuropeptide Y and peptide YY as possible cerebrospinal fluid markers for major depression and schizophrenia, respectively. J Psychiatr Res 22:69-79.
95. Wolak ML, deJoseph MR, Cator AD, Mokashi AS, Brownfield MS, Urban JH. 2003. Comparative distribution of neuropeptide Y Y1 and Y5 receptors in the rat brain by using immunohistochemistry. J Comp Neurol 464:285-311.
96. Yatham LN. 2004. Newer anticonvulsants in the treatment of bipolar disorder. J Clin Psychiatry 65(Suppl 10):28-35.
97. Zigmond RE, Sun Y. 1997. Regulation of neuropeptide expression in sympathetic neurons. Paracrine and retrograde influences. Ann N Y Acad Sci 814:181-197.
98. Zukowska Z, Pons J, Lee EW, Li L. 2003. Neuropeptide Y: a new mediator linking sympathetic nerves, blood vessels and immune system? Can J Physiol Pharmacol 81:89-94.